Investor Relations

Press Releases

Date Title and Summary View
Nov 14, 2019
PRINCETON, N.J. , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the U.S. Food and Drug Administration ( FDA ) has extended the Prescription Drug User Fee Act (PDUFA) goal date for its review of the New Drug Application
Oct 30, 2019
Committee Votes 14 to 1, with 1 Abstention, in Favor of Approval PRINCETON, N.J. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a positive outcome from today’s meeting of the Bone, Reproductive and Urologic Drugs Advisory
Oct 28, 2019
FDA Advisory Committee Meeting for Twirla® NDA Scheduled for October 30, 2019 Cash Expected to Enable Company to Fund Operations through end of First Quarter 2020 PRINCETON, N.J. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today
Sep 06, 2019
PRINCETON, N.J. , Sept. 06, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics , Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari, will present at two upcoming investor conferences in New York City , where he will provide an
Aug 08, 2019
PRINCETON, N.J. , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their option to purchase an additional 1,894,736 shares
Aug 02, 2019
PRINCETON, N.J. , Aug. 02, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 12,631,579 shares of its common stock at a public offering price of $0.95 per share.
Aug 01, 2019
PRINCETON, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. 
Aug 01, 2019
FDA Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 Cash Expected to Enable Company to Fund Operations through the End of 2019 PRINCETON, N.J. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported
Jul 18, 2019
Dennis P. Reilly to bring commercial experience to management team Appointment Effective August 5, 2019 PRINCETON, N.J. , July 18, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Dennis P.
Jun 24, 2019
Meeting Scheduled for October 30, 2019 FDA Previously Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 PRINCETON, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that a meeting of the Bone,